News Headlines Article

F.D.A. Advisory Panel Votes to Approve Diabetes Drug
New York Times

A federal advisory panel voted 10 to 5 on Thursday to approve a diabetes drug that could be the first in a new class of drugs in the United States to treat the disease, although several members raised concerns about potential cardiovascular risks and its use in people whose kidneys are impaired. The drug, canagliflozin, is being developed by Johnson & Johnson and is part of a new group of drugs that lowers blood sugar by causing blood sugar to be excreted in the urine. Many existing treatments work by affecting the supply or use of insulin.